Switch to: References

Add citations

You must login to add citations.
  1. Institutional Corruption and the Pharmaceutical Policy.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):544-552.
    Today, the goals of pharmaceutical policy and medical practice are often undermined due to institutional corruption — that is, widespread or systemic practices, usually legal, that undermine an institution's objectives or integrity. In this symposium, 16 articles investigate the corruption of pharmaceutical policy, each taking a different look at the sources of corruption, how it occurs, and what is corrupted. We will see that the pharmaceutical industry's own purposes are often undermined. Furthermore, pharmaceutical industry funding of election campaigns and lobbying (...)
    Download  
     
    Export citation  
     
    Bookmark  
  • Biosecurity and Open-Source Biology: The Promise and Peril of Distributed Synthetic Biological Technologies.Nicholas G. Evans & Michael J. Selgelid - 2015 - Science and Engineering Ethics 21 (4):1065-1083.
    In this article, we raise ethical concerns about the potential misuse of open-source biology : biological research and development that progresses through an organisational model of radical openness, deskilling, and innovation. We compare this organisational structure to that of the open-source software model, and detail salient ethical implications of this model. We demonstrate that OSB, in virtue of its commitment to openness, may be resistant to governance attempts.
    Download  
     
    Export citation  
     
    Bookmark   5 citations  
  • COVID-19 vaccine boosters for young adults: a risk benefit assessment and ethical analysis of mandate policies at universities.Kevin Bardosh, Allison Krug, Euzebiusz Jamrozik, Trudo Lemmens, Salmaan Keshavjee, Vinay Prasad, Marty A. Makary, Stefan Baral & Tracy Beth Høeg - 2024 - Journal of Medical Ethics 50 (2):126-138.
    In 2022, students at North American universities with third-dose COVID-19 vaccine mandates risk disenrolment if unvaccinated. To assess the appropriateness of booster mandates in this age group, we combine empirical risk-benefit assessment and ethical analysis. To prevent one COVID-19 hospitalisation over a 6-month period, we estimate that 31 207–42 836 young adults aged 18–29 years must receive a third mRNA vaccine. Booster mandates in young adults are expected to cause a net harm: per COVID-19 hospitalisation prevented, we anticipate at least (...)
    Download  
     
    Export citation  
     
    Bookmark   4 citations